ACADIA Pharmaceuticals, which is developing treatments for central nervous system and neurological disease, said this morning that it has received funding from Fast Forward LLC, a nonprofit established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck. ACADIA said the $545,000 from the two will go towards preclinical studies for its AC-186 compound, which is being approached as a new treatment of multiple sclerosis. ACADIA said the new funds will go towards research being conducted in collaboration with Dr. Rhonda Voskuhl of UCLA.
Top NewsThursday, December 20, 2012
ACADIA Pharmaceuticals Get Research Funding